Mega Genomics Balans Gezondheid
Financiële gezondheid criteriumcontroles 5/6
Mega Genomics has a total shareholder equity of CN¥662.6M and total debt of CN¥21.7M, which brings its debt-to-equity ratio to 3.3%. Its total assets and total liabilities are CN¥832.1M and CN¥169.4M respectively. Mega Genomics's EBIT is CN¥32.0M making its interest coverage ratio -8.2. It has cash and short-term investments of CN¥508.9M.
Belangrijke informatie
3.3%
Verhouding schuld/eigen vermogen
CN¥21.69m
Schuld
| Rente dekkingsratio | -8.2x |
| Contant | CN¥508.93m |
| Aandelen | CN¥662.64m |
| Totaal verplichtingen | CN¥169.43m |
| Totaal activa | CN¥832.07m |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Shareholders Will Be Pleased With The Quality of Mega Genomics' (HKG:6667) Earnings
Oct 03
Returns On Capital Signal Tricky Times Ahead For Mega Genomics (HKG:6667)
Aug 28Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03Calculating The Intrinsic Value Of Mega Genomics Limited (HKG:6667)
Feb 20Mega Genomics Limited's (HKG:6667) Share Price Could Signal Some Risk
Aug 12A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)
Nov 07Analyse van de financiële positie
Kortlopende schulden: 6667's short term assets (CN¥710.9M) exceed its short term liabilities (CN¥131.0M).
Langlopende schulden: 6667's short term assets (CN¥710.9M) exceed its long term liabilities (CN¥38.4M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 6667 has more cash than its total debt.
Schuld verminderen: Insufficient data to determine if 6667's debt to equity ratio has reduced over the past 5 years.
Schuldendekking: 6667's debt is well covered by operating cash flow (513.3%).
Rentedekking: 6667 earns more interest than it pays, so coverage of interest payments is not a concern.